Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Taxol/Ifosfamide and Carboplatin/Etoposide with Stem Cell Support in Cisplatin-Resistant Germ Cell Tumors
NCT00002558Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 1994
- Primary completion
- Apr 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin in germ cell tumor (GCT), ovarian cancer and Testicular Germ Cell Tumor (TGCT), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Objective Response at 2 years. Started Jan 1994; status: completed.
02
Drugs
carboplatin
03
Conditions
germ cell tumor (GCT)ovarian cancerTesticular Germ Cell Tumor (TGCT)
Beyond the preview
Go deeper on NCT00002558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002558.